Nath Bio-Genes

Market Cap: Micro Cap
Industry: Other Agricultural Products
ISIN: INE448G01010
NSEID: NATHBIOGEN
BSEID: 537291
View on NSE | View on BSE

INR

158.80

-3 (-1.85%)

BSENSE

Aug 07, 03:30 PM

BSE+NSE Vol: 59.29 k

{
  "main_header": {
    "sid": 628630,
    "name": "Nath Bio-Genes",
    "stock_name": "Nath Bio-Genes",
    "full_name": "Nath Bio-Genes (India) Ltd",
    "name_url": "stocks-analysis/nath-bio-genes",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "158.80",
    "chg": -3,
    "chgp": "-1.85%",
    "dir": -1,
    "prev_price": "161.80",
    "mcapval": "302.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 537291,
    "symbol": "NATHBIOGEN",
    "ind_name": "Other Agricultural Products",
    "ind_code": 107,
    "sector_id": 53,
    "indexname": "India SENSEX",
    "isin": "INE448G01010",
    "curr_date": "Aug 07, 03:30 PM",
    "curr_time": "03:38 AM",
    "last_traded_at": "Aug 07, 03:30 PM IST",
    "bse_nse_vol": "59.29 k",
    "exc_status": "Active",
    "traded_date": "Aug 07, 2026",
    "traded_date_str": "2026 08 07",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/nath-bio-genes-628630-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Nath Bio-Genes (India) Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/nath-bio-genes-india-ltd-is-rated-sell-4139572",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/NathBioGenesInd_mojoScore_4139572.png",
        "date": "2026-08-06 10:11:57",
        "description": "Nath Bio-Genes (India) Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 22 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 06 August 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Are Nath Bio-Genes (India) Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-nath-bio-genes-india-ltd-latest-results-good-or-bad-4129054",
        "imagepath": "",
        "date": "2026-07-30 19:20:25",
        "description": "Nath Bio-Genes (India) Ltd reported its financial results for Q1 FY27, showcasing a notable performance in terms of net sales and net profit. The company achieved net sales of ₹328.40 crores, reflecting a year-on-year growth of 15.76% compared to ₹283.70 crores in Q1 FY26. This growth is indicative of the seasonal strength typically seen in the agricultural sector, particularly in the first quarter, which aligns with peak harvest and trading periods.\n\nThe net profit for the quarter stood at ₹32.26 crores, marking a year-on-year increase of 14.07%, a significant recovery from a marginal loss in the previous quarter (Q4 FY26). However, it's important to note that the profit margins exhibited some compression, with the PAT margin slightly decreasing to 9.82% from 9.97% in Q1 FY26, suggesting that while sales growth is present, it hasn't fully translated into proportional profit growth.\n\nThe operating profit (P..."
      },
      {
        "title": "Nath Bio-Genes Q1 FY27: Strong Profit Surge Masks Underlying Quality Concerns",
        "link": "https://www.marketsmojo.com/news/result-analysis/nath-bio-genes-q1-fy27-strong-profit-surge-masks-underlying-quality-concerns-4127576",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/NathBioGenesInd_quaterlyResult_4127576.png",
        "date": "2026-07-29 21:31:29",
        "description": "Nath Bio-Genes (India) Ltd., a micro-cap agricultural products company with a market capitalisation of ₹319.00 crores, reported a consolidated net profit of ₹32.26 crores for Q1 FY27, representing a remarkable year-on-year growth of 14.07% from ₹28.28 crores in Q1 FY26. However, the stock has declined 1.47% following the results announcement, closing at ₹161.15, as investors grapple with the company's persistent quality challenges and weak long-term fundamental strength."
      },
      {
        "title": "Nath Bio-Genes (India) Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/nath-bio-genes-india-ltd-is-rated-sell-4121039",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/NathBioGenesInd_mojoScore_4121039.png",
        "date": "2026-07-26 10:10:40",
        "description": "Nath Bio-Genes (India) Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 22 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 July 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing."
      },
      {
        "title": "Nath Bio-Genes (India) Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/nath-bio-genes-india-ltd-is-rated-sell-4103595",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/NathBioGenesInd_mojoScore_4103595.png",
        "date": "2026-07-15 10:11:30",
        "description": "Nath Bio-Genes (India) Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 22 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 15 July 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance."
      },
      {
        "title": "Nath Bio-Genes (India) Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/nath-bio-genes-india-ltd-is-rated-sell-4088270",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/NathBioGenesInd_mojoScore_4088270.png",
        "date": "2026-07-04 10:10:47",
        "description": "Nath Bio-Genes (India) Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 22 June 2026. However, all fundamentals, returns, and financial metrics discussed here reflect the stock's current position as of 04 July 2026, providing investors with the most up-to-date analysis."
      },
      {
        "title": "Nath Bio-Genes Downgraded to Sell Amid Weak Fundamentals and Mixed Technicals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/nath-bio-genes-downgraded-to-sell-amid-weak-fundamentals-and-mixed-technicals-4068418",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/NathBioGenesInd_mojoScore_4068418.png",
        "date": "2026-06-23 08:42:02",
        "description": "Nath Bio-Genes (India) Ltd, a micro-cap player in the Other Agricultural Products sector, has seen its investment rating downgraded from Hold to Sell as of 22 June 2026. This adjustment reflects a complex interplay of factors including a shift in technical indicators, subdued financial trends, valuation considerations, and overall quality assessments. Despite a modest uptick in share price, the company’s long-term fundamentals and market performance continue to raise concerns for investors."
      },
      {
        "title": "Nath Bio-Genes Upgraded to Hold as Technicals Improve Amid Flat Financials",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/nath-bio-genes-upgraded-to-hold-as-technicals-improve-amid-flat-financials-4055433",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/NathBioGenesInd_mojoScore_4055433.png",
        "date": "2026-06-16 08:46:15",
        "description": "Nath Bio-Genes (India) Ltd, a micro-cap player in the Other Agricultural Products sector, has seen its investment rating upgraded from Sell to Hold as of 15 June 2026. This revision reflects a nuanced assessment across four key parameters: quality, valuation, financial trend, and technicals. While the company continues to face challenges in long-term growth and profitability, recent technical indicators and valuation metrics have improved sufficiently to warrant a more cautious but optimistic stance."
      },
      {
        "title": "Nath Bio-Genes Falls 3.53%: 2 Key Factors Driving This Week’s Decline",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/nath-bio-genes-falls-353-2-key-factors-driving-this-weeks-decline-4052376",
        "imagepath": "",
        "date": "2026-06-13 17:21:45",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>1 June:</strong> Formation of Golden Cross signalling potential bullish breakout</p>\n                    <p><strong>2 June:</strong> Upgrade to Hold rating by MarketsMOJO on technical and valuation improvements</p>\n                    <p><strong>5 June:</strong> Stock closes the week lower at Rs.169.35 (-3.53%)</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.175.55</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.169.35</div><div class=\"stat-change negative\">-3.53%</div></div>\n     ..."
      }
    ],
    "total": 178,
    "sid": "628630",
    "stock_news_url": "https://www.marketsmojo.com/news/nath-bio-genes-india-628630"
  },
  "announcements": [
    {
      "caption": "Announcement Under Reg 30 Of SEBI (LODR)",
      "datetime": "06-Aug-2026",
      "details": "Intimation of Initiation of Forensic Audit",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
      "datetime": "30-Jul-2026",
      "details": "Investor Presentation on Unaudited Financial Results as of 30th June 2026",
      "source": "BSE"
    },
    {
      "caption": "Financial Results As Of 30Th June 2026.",
      "datetime": "29-Jul-2026",
      "details": "Outcome of Board Meeting: Unaudited Financial results as of 30th June 2026.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Nath Bio-Genes (India) Ltd has declared <strong>20%</strong> dividend, ex-date: 14 Aug 25",
          "dt": "2025-08-14",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Nath Bio-Genes (India) Ltd is Rated Sell

2026-08-06 10:11:57

Nath Bio-Genes (India) Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 22 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 06 August 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Are Nath Bio-Genes (India) Ltd latest results good or bad?

2026-07-30 19:20:25

Nath Bio-Genes (India) Ltd reported its financial results for Q1 FY27, showcasing a notable performance in terms of net sales and net profit. The company achieved net sales of ₹328.40 crores, reflecting a year-on-year growth of 15.76% compared to ₹283.70 crores in Q1 FY26. This growth is indicative of the seasonal strength typically seen in the agricultural sector, particularly in the first quarter, which aligns with peak harvest and trading periods. The net profit for the quarter stood at ₹32.26 crores, marking a year-on-year increase of 14.07%, a significant recovery from a marginal loss in the previous quarter (Q4 FY26). However, it's important to note that the profit margins exhibited some compression, with the PAT margin slightly decreasing to 9.82% from 9.97% in Q1 FY26, suggesting that while sales growth is present, it hasn't fully translated into proportional profit growth. The operating profit (P...

Read full news article

Nath Bio-Genes Q1 FY27: Strong Profit Surge Masks Underlying Quality Concerns

2026-07-29 21:31:29

Nath Bio-Genes (India) Ltd., a micro-cap agricultural products company with a market capitalisation of ₹319.00 crores, reported a consolidated net profit of ₹32.26 crores for Q1 FY27, representing a remarkable year-on-year growth of 14.07% from ₹28.28 crores in Q1 FY26. However, the stock has declined 1.47% following the results announcement, closing at ₹161.15, as investors grapple with the company's persistent quality challenges and weak long-term fundamental strength.

Read full news article

Nath Bio-Genes (India) Ltd is Rated Sell

2026-07-26 10:10:40

Nath Bio-Genes (India) Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 22 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 July 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Read full news article

Nath Bio-Genes (India) Ltd is Rated Sell

2026-07-15 10:11:30

Nath Bio-Genes (India) Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 22 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 15 July 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Read full news article

Nath Bio-Genes (India) Ltd is Rated Sell

2026-07-04 10:10:47

Nath Bio-Genes (India) Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 22 June 2026. However, all fundamentals, returns, and financial metrics discussed here reflect the stock's current position as of 04 July 2026, providing investors with the most up-to-date analysis.

Read full news article

Nath Bio-Genes Downgraded to Sell Amid Weak Fundamentals and Mixed Technicals

2026-06-23 08:42:02

Nath Bio-Genes (India) Ltd, a micro-cap player in the Other Agricultural Products sector, has seen its investment rating downgraded from Hold to Sell as of 22 June 2026. This adjustment reflects a complex interplay of factors including a shift in technical indicators, subdued financial trends, valuation considerations, and overall quality assessments. Despite a modest uptick in share price, the company’s long-term fundamentals and market performance continue to raise concerns for investors.

Read full news article

Nath Bio-Genes Upgraded to Hold as Technicals Improve Amid Flat Financials

2026-06-16 08:46:15

Nath Bio-Genes (India) Ltd, a micro-cap player in the Other Agricultural Products sector, has seen its investment rating upgraded from Sell to Hold as of 15 June 2026. This revision reflects a nuanced assessment across four key parameters: quality, valuation, financial trend, and technicals. While the company continues to face challenges in long-term growth and profitability, recent technical indicators and valuation metrics have improved sufficiently to warrant a more cautious but optimistic stance.